Locally Recurrent Prostate Tumors Following Either Radiation Therapy or Radical Prostatectomy Have Changes in Ki-67 Labeling Index, P53 and BCL-2 Immunoreactivity

Grossfeld, Gary D.; Olumi, Aria F.; Connolly, John A.; Chew, Karen; Gibney, Jennifer; Bhargava, Vivek; Waldman, Frederic M.; Carroll, Peter R.

doi:10.1097/00005392-199805000-00004

Cited by 79 publications

(36 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The expression of p53 correlates with tumour progression and prognosis. 24,25 In our study, Bcl-2 and p53 did not show any significant change during IAS, nor did they correlate with the first offtreatment time. It remains unclear whether this reflects the unpredictable biological behaviour of hormonally treated advanced PC or is simply a shortcoming of our study.…”

Section: Discussioncontrasting

confidence: 65%

Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression

Augustin

Freibauer²,

Bayer³

et al. 2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Objective: Tumour features were evaluated during intermittent androgen suppression (IAS), and their prognostic impact on the first off-treatment time was analysed. Patients and methods: Twenty patients with advanced prostate cancer underwent three consecutive prostate biopsies during the first cycle, namely at the beginning of androgen deprivation, 8 months after continuous therapy and at the time of prostate-specific antigen (PSA) progression above 20 ng/ml. Biopsy specimens were immunohistochemically processed and analysed for the apoptotic index (AI), Ki-67, p53 and Bcl-2 to investigate eventual changes over time. Correlations and regression analysis were performed to assess the prognostic significance of clinical and pathological parameters in predicting the first off-treatment time. Results: In contrast to the AI, p53 and Bcl-2, Ki-67 was the only marker that significantly changed over time (P ¼ 0.008). The first off-treatment time correlated significantly with pretreatment PSA (r ¼ À0.594; Po0.01), testosterone recovery time (r ¼ 0.590; P ¼ 0.013) and biopsy grade (r ¼ À0.738; Po0.01); only the latter gaining an independent factor in the multivariate analysis (P ¼ 0.022). Conclusions: During IAS, Ki-67 was the only molecular marker that consistently changed over time. However, it did not correlate with off-treatment time that was predicted independently by the initial biopsy grade only. First off-treatment time was best predicted by clinical parameters and molecular markers from needle biopsies did not further contribute to a better patient selection.

show abstract

Section: Discussioncontrasting

confidence: 65%

Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression

Augustin

Freibauer²,

Bayer³

et al. 2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Interphase cytogenetics for chromosomes 7,8,17, and X revealed a normal (disomic) chromosomal status in four cases. The remaining 10 tumours exhibited focal gains of signal counts at least for some of the chromosomes studied.…”

Section: Large Prostate Cancers In the Transition Zone A Erbersdoblermentioning

confidence: 95%

“…A case was considered positive for p53 or bcl-2 expression when at least 5% of tumour cells were marked by the corresponding antibody. 8,9 No further quantification according to the number of positive cells or the intensity of staining was performed.…”

Section: Immunohistochemistrymentioning

confidence: 99%

“…Chromogenic in situ hybridisations (CISH) were performed on selected 5 -6 mm thick paraffin sections as described previously, 10 using digoxigenated nucleic acid probes specific for chromosomes 7,8,17, and X (Oncor, Gaithersburg, MD). Briefly, pretreatment of the slides consisted of boiling in 10 mM citric acid monohydrate in a microwave oven for 30 s, followed by an incubation with 1 M sodium thiocyanate for 10 min at 80 C. The slides were then digested with pepsin (2 -4 mg/ml in 0.2 M hydrochloric acid) at 37 C for 2 -8 min.…”

Section: Interphase Cytogeneticsmentioning

confidence: 99%

See 1 more Smart Citation

Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone

Erbersdobler

Huhle

Palisaar

et al. 2002

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Prostate carcinomas located in the transition zone are suspected to behave differently from the more frequent peripheral zone cancers. In this study, large transition zone prostate cancers were investigated for pathological and clinical features. From 365 consecutive radical prostatectomy specimens, 73 cases were disclosed with tumours larger than 10 cm 3 . Of these, 14 were predominantly (>70% tumour area) located in the transition zone. Pathological investigations included a complete histological work-up, immunohistochemistry for p53 and bcl-2, and interphase cytogenetics for chromosomes 7, 8, 17, and X. Despite large tumour volumes and high preoperative prostate specific antigen (PSA)-values, most tumours showed quite favourable pathological features. Only two of these patients suffered from a postoperative PSA-recurrence during a median followup of 50 months. For comparison, 36 cases that contained tumours predominantly located in the peripheral zone mostly displayed adverse prognostic signs and 68.8% of these patients suffered from postoperative PSA-recurrence. We conclude that the peculiar pathological and clinical characteristics of large prostate cancers in the transition zone might be important for prognostic considerations.

show abstract

“…27 Cellular proliferation is increased in recurrent prostate tumours after radiotherapy or surgery. 28 Many aberrant pathways in tumours could lead to increased cellular proliferation and a wide range of aberrant signal transduction pathways have been implicated in prostate cancer, including EGFR signalling (Figure l). 27,29 Cross-talk between the androgen and EGFR signalling pathways may play a signi®cant role in prostate cancer development, as androgen has been shown to up-regulate EGFR expression in PC-3 cells expressing the androgen receptor (AR).…”

Section: Introductionmentioning

confidence: 99%

Anti-EGF receptor therapy

Blackledge

Averbuch

Kay

et al. 2000

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Locally Recurrent Prostate Tumors Following Either Radiation Therapy or Radical Prostatectomy Have Changes in Ki-67 Labeling Index, P53 and BCL-2 Immunoreactivity

Abstract: Recurrent tumors following either radiation or surgery differ significantly from the corresponding pretreatment tumors with respect to cellular proliferation and p53 nuclear reactivity.

Cited by 79 publications

References 22 publications

Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression

Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression

Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone

Anti-EGF receptor therapy

Contact Info

Product

Resources

About